Dr Farasat Kazmi
FRCR (Clinical Oncology) MRCP MRCS MSc (Oxford)
Languages spoken
English
Expert in
Lung Cancers & Stereotactic Ablative Radiotherapy
Overview
Dr Farasat Kazmi is a Consultant Clinical Oncologist specialising in lung cancer, with particular expertise in advanced radiotherapy techniques including Stereotactic Ablative Radiotherapy (SABR). He treats lung cancer across all stages, from early-stage disease to locally advanced and metastatic cancer, using modern radiotherapy alongside chemotherapy, immunotherapy, and precision-targeted therapies guided by molecular profiling.
Dr Kazmi has a strong academic and research background and holds an MSc in Nanomedicine from the University of Oxford. He previously worked in the Early Phase Clinical Trials Unit at the Churchill Hospital, Oxford, where he was involved in first-in-human and novel targeted therapy studies. He is the Principal Investigator on three international lung cancer clinical trials and has played a leading role in Cochrane systematic reviews on genomic-guided cancer therapies, ensuring his clinical practice is firmly grounded in the highest-quality evidence.
He is known for his clear communication, calm manner, and patient-centred approach, taking time to explain diagnoses and treatment options and supporting shared decision-making throughout the cancer journey.
Being told you have lung cancer can be life-changing, and no two patients’ journeys are the same. I take a personalised, evidence-based approach to care, using the latest advances in radiotherapy and systemic treatments while never losing sight of the person behind the diagnosis. I see my role as not only delivering the best possible treatment, but also supporting you with clear communication, reassurance, and shared decision-making throughout your care
.svg){kind=icon}
Career positions
- Consultant Clinical Oncologist GenesisCare Bristol & Cambridge
Expertise and interests
He is actively involved in precision oncology, leading institutional initiatives focused on integrating molecular testing and personalised treatment strategies into routine cancer care. His work has been recognised through national and international awards, including competitive oncology research and education grants.
Professional memberships
- GMC Specialist Registration in Clinical Oncology (Oct 2025)
- European Society of Medical Oncology (ESMO)
- Fellowship of the Royal College of Radiologists (May 2024)
- Membership of the European Society of Medical Oncology (2022)
- Membership of the Royal College of Physicians (2021)
- Membership of the Royal College of Surgeons (2018)
Awards received
- September 2025 – Scientific Advisory Committee Member at the World Conference on Lung Cancer 2025 (WCLC). Invited to Advisory Board Data Readouts, Barcelona
- November 2023 – Recipient of the Cancer Research Excellence Early Career Researcher Award, Cambridg. Awarded by the National Institute for Health and Care Research (NIHR)
- October 2023 – Recipient of the ESMO Merit Travel Grant, Paris. Oral presentation at ESMO Molecular Analysis for Precision Oncology
- May 2023 – Recipient of the ESMO Preceptorship Colorectal Cancer Education Grant, Valencia. Presented case: “A DPYD Variant with mCRC and Inoperable Liver Metastases”